Thesis – a company that offers a customized approach to cognitive performance products based on your unique brain chemistry – announced that it has raised over $13.5 million in funding. The company had recently closed on a Series A round totaling $8.4 million with investors that included Unilever Ventures, Redo Ventures, Alive VC, Break Trail, NBA superstar Kevin Love and model Kate Bock. Previously the company raised $5.1 million in an undisclosed seed round that included Unilever Ventures, MBX, Trust Ventures and Redo Ventures.
The company recognizes that nootropics are not a one-size-fits-all wellness category. And through the highest quality ingredients and a customized approach, the brand helps people effectively boost their cognition & productivity.
The new funding round will support Thesis as it makes key executive hires, expands out its product selection and undergoes clinical trials. And Thesis’ products are formulated with clinically studied active ingredients with the highest possible bioavailability and adhere to the FDA Current Good Manufacturing Processes (cGMP).
KEY QUOTES:
“Nootropics have helped me a great deal, as someone who originally struggled in school and who eventually went on to graduate from some of the world’s most prestigious universities. I spent a significant amount of time learning about these compounds and finding the blend that worked for me. It shouldn’t be so hard, I created Thesis products for people who feel that they might not be living up to their full potential and want a real solution to close the gap.”
— Dan Freed, founder and CEO of Thesis
“In today’s ‘always on’ world, consumers are increasingly looking for solutions to optimize their mental acuity and the demand for products that allow you to perform at your best has never been greater. With Thesis’s customized offering, education-focused and digital-first model rooted in a highly compelling founder story, we have been impressed by Dan’s vision and the exacting standards that he is setting for the brand. We are excited to support him on the next chapter of the business’s growth.”
— Rachel Harris, Partner at Unilever Ventures
“I am excited to be part of Dan’s vision of customized health and wellness solutions. Thesis is defining a new wellness category and reshaping how people approach brain care.”
— Michael Lynton, Thesis Board Director
